Stock Analysis of Aprea Therapeutics Inc (APRE) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code APRE
Close 5.27
Change -0.320 / 5.72 %
Volume 7979.00
Vol Change -6772.00 / 45.91 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Low Growth Stock
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Aprea Therapeutics Inc
PE (TTM)

-1.60

Very Poor
Price / Book

0.845

Very Good
Price / Sales

21.05

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

28617.26 K

Enterprise Value

7010.44 K

ROA (TTM)

-44.68

Very Poor
ROE (TTM)

-54.17

Very Poor
Net Margin (TTM)

-1319.46

Very Poor
Revenue

%

583231
Net Profit

88.21 %

-13285.64 K
Debt to Equity

0

Excellent
Altman Z Score

-16.98

Very Poor
Quick Ratio

0

Poor
Cash Ratio

4.93

Very Good


Highs/Lows of Aprea Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week5.59 5.72 % 1.54 % 5.95.249916-May-2413-May-24
Two Week5.35 1.50 % 3.42 % 5.95.048516-May-2408-May-24
One Month5.73 8.03 % 5.60 % 5.94.900116-May-2430-Apr-24
Three Month5.828 9.57 % 5.95 % 8.84654.900101-Mar-2430-Apr-24
Six Months3.77 39.79 % 17.48 % 8.84653.500101-Mar-2412-Dec-23
One year3.84 37.24 % 27.52 % 8.84652.7801-Mar-2407-Jul-23
Two year0.677 678.43 % 29.70 % 10.60.30410-Feb-2330-Dec-22


Technical View of Aprea Therapeutics Inc
RSI

43.47

Neutral
MACD

-0.071

Bullish
ADX

19.64

Bearish
Super Trend

6.06

Mild Bearish
Williams %R

-63.01

Neutral
CCI

40.40

Strong Bearish


EMA 5

5.52

Strong Bearish
EMA 15

5.50

Strong Bearish
EMA 50

5.71

Neutral
EMA 100

5.59

Neutral
SMA 100

5.88

Mild Bearish
SMA 200

4.95

Bullish
SMA 5 / 20

5.63 / 5.36

Strong Bullish
SMA 15 / 50

5.40 / 5.84

Mild Bearish
SMA 50 / 200

5.84 / 4.95

Bullish




Charts of Aprea Therapeutics Inc


Returns of Aprea Therapeutics Inc with Peers
Period / StockAPREDRRXICUFRLN
1 Week-5.72%-12.26%-4.14%0.778%
1 Mth-8.03%5.92%-44.77%1.09%
3 Mth-9.57%-10.58%-66.70%37.58%
6mth39.79%51.79%-29.79%65.73%
1 Year37.24%-82.45%-34.53%-20.00%
2 Year678.43%-77.79%--64.88%
5 Years--87.53%--
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Aprea Therapeutics Inc with Peers
Ratio / StockAPREDRRXICUFRLN
PE-1.60-1.12-0.416-4.38
P/B0.8452.20-0.9434.40
ROA-44.68-47.87-1123.52-65.71
ROE-54.17-196.440-100.25
Debt To Equity01.22-0.5500
Revenue583231
% 		9194.00 K
52.32 % 		0
% 		622000
0.810 %
Net Income-13285.64 K
88.21 % 		-36652.00 K
3.73 % 		-35572.00 K
54.57 % 		-49932.00 K
43.88 %


Technicals of Aprea Therapeutics Inc with Peers
Technical / StockAPREDRRXICUFRLN-
ADX19.6418.9317.0639.19
CMF0.1930.091-0.1890.159
MFI52.4145.0541.4883.29
RSI43.4745.4638.7461.01
MACD Abv SignalTrueFalseTrueFalse
Price Above 50 MAFalseFalseFalseTrue-
Price Above 200 MATrueFalseFalseTrue-


About : Aprea Therapeutics Inc

Address : 3805 Old Easton Road, Doylestown, PA, United States, 18902
Tel : 617 463 9385
URL : https://www.aprea.com
Code : APRE, ISIN : US03836J1025, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 03_Oct_2019
Employee Count : 7

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.


Note : All Data Generated at the End of Trading Hours (EOD Data)